Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
354 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (2)

Medical Condition

  • Show all (90)
  • Autoimmune Disorders (1)
  • Blood Disorders (4)
  • Bone & Muscle (1)
  • Cancer (23)
    • Breast Cancer (1)
    • Gynecologic Cancer (2)
    • Head and Neck Cancer (1)
    • Leukemia (3)
    • (-) Liver Cancer (1)
    • Lung Cancer (2)
    • Lymphoma (1)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (1)
    • Prostate Cancer (1)
    • Solid Tumors (2)
    • Uveal Melanoma (2)
  • COVID-19 (Coronavirus) (4)
  • Diabetes (2)
  • Endocrine & Metabolic Disease (3)
  • Healthy Volunteers (10)
  • Heart Disease (17)
  • Kidney Disease (1)
  • Liver Disease (1)
  • Lung Disease (2)
  • Neurological Disorders (3)
    • (-) Alzheimer's Disease (1)
    • Neuropathy (1)
  • Nutrition (1)
  • Obesity (2)
  • Obstetrics & Gynecology (3)
  • Pediatrics (7)
  • Surgery (2)
  • Transplant (3)
Displaying 1 - 2 of 2

A Study of Atezolizumab Plus Bevacizumab Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence

Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus bevacizumab versus observation (not receiving any treatment) on patients with completely resected (surgically removed) or ablated (removed using heat) hepatocellular carcinoma (the most common type of liver cancer) who are at high risk for…
Read More

A study for patients with Progressive Supranuclear Palsy (PCP) using study drug C2N-8E12

Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Lawrence Honig, MD, PhD
Status: Closed
The purpose of this Phase I study is to see whether a single dose of an experimental drug (meaning a drugthat is not approved by the FDA) called C2N-8E12 given into your vein (called intravenous or IV) is safeand well-tolerated in subjects with Progressive Supranuclear Palsy (PSP). C2N-8E12 is an immunotherapy (antibody) drug designed to bind to and to…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science